DOW JONES27,647.00-313.80 -1.12%
S&P 5003,187.98-37.91 -1.18%
NASDAQ9,098.32-122.96 -1.33%

Karyopharm Submits New Drug Application to the FDA for XPOVIO as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Benzinga · 12/23/2019 12:42